PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
Pieris Pharmaceuticals, Inc. (PIRS)
NASDAQ:AMEX Investor Relations:
ir.pieris.com
Company Research
Source: Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Palvella Therapeutics, Inc. is fair to Pieris shareholders. Pre-merger Pieris shareholders are expected to own approximately 18% of the combined company.Halper Sadeh encourages Pieris shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether Pieris and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Pieris shareholders; and (2) disclose all material information necessary for Pieris shareholders to adequately assess and value the merger consideration.On behalf of Pieris shareholders, Halper Sadeh LLC may seek increased conside
Show less
Read more
Impact Snapshot
Event Time:
PIRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PIRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PIRS alerts
High impacting Pieris Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PIRS
News
- Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial OfficerGlobeNewswire
- Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations [Yahoo! Finance]Yahoo! Finance
- Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) [Yahoo! Finance]Yahoo! Finance
- We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
PIRS
Earnings
- 11/14/23 - In-Line
PIRS
Sec Filings
- 11/5/24 - Form S-4/A
- 10/29/24 - Form S-4/A
- 10/28/24 - Form 4
- PIRS's page on the SEC website